US stocks surged | Eli Lilly (LLY.US) rose nearly 3% and reached a collaboration with Crystal Technology in the field of bispecific antibodies AI large molecule research and development.

According to the Wise Financial APP, on Wednesday, Eli Lilly (LLY.US) rose nearly 3% to $933.34. On the news front, Jingtai Technology announced that its wholly-owned subsidiary Ailux has reached a strategic cooperation and platform authorization agreement with Eli Lilly, with a total value of up to $345 million, including tens of millions of dollars in upfront payments and recent milestone payments. According to the agreement, Eli Lilly can nominate multiple targets, and Ailux is responsible for designing and optimizing dual antibody candidate drugs. Ailux is eligible to receive tens of millions of dollars in upfront payments and recent milestone payments, as well as subsequent research and development, registration and commercial milestone payments. In addition, Eli Lilly also has the right to use Ailux's artificial intelligence dual antibody design platform.